{
  "ticker": "JNJ",
  "target_date": "2025-10-08",
  "actual_date": "2025-10-08",
  "collected_at": "2025-12-08T12:22:49.817145",
  "price": {
    "open": 187.68,
    "high": 189.02,
    "low": 187.08,
    "close": 188.49322509765625,
    "volume": 5751200,
    "change_1d_pct": 0.42,
    "change_7d_pct": 4.44,
    "change_30d_pct": 7.48
  },
  "technicals": {
    "rsi_14": 87.71,
    "sma_20": 179.73,
    "sma_50": 175.72,
    "macd": 3.66,
    "macd_signal": 2.72,
    "macd_histogram": 0.94,
    "bb_upper": 190.39,
    "bb_lower": 169.07,
    "price_vs_sma20_pct": 4.88,
    "price_vs_sma50_pct": 7.27,
    "volume_ratio": 0.66
  },
  "fundamentals": {
    "market_cap": 487773831168,
    "pe_ratio": 19.541988,
    "forward_pe": 19.099527,
    "price_to_book": 6.1448693,
    "price_to_sales": 5.293317,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.58,
    "pct_from_52w_low": 43.91
  },
  "macro": {
    "spy": {
      "price": 673.11,
      "change_1d_pct": 0.6,
      "change_7d_pct": 1.04
    },
    "vix": {
      "level": 16.3,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.13
    },
    "dollar_index": {
      "level": 98.85
    },
    "gold": {
      "price": 4043.3
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Finally, Tariffs the Stock Market Likes. Why Pharma Levies May Do the Trick.",
      "source": "Yahoo",
      "datetime": 1759949280,
      "summary": "Unlike the broad reciprocal tariffs announced on April 2, which triggered a market crash, Trump\u2019s new drug tariffs, announced in conjunction with a new government-run drug sales platform last month, seems to have boosted investor confidence.  Stocks of major pharmaceutical firms, including  Eli Lill",
      "url": "https://finnhub.io/api/news?id=fde8b62877dcbe4bf2b03b87a111b78c324445ab22863a4ab7e9d31e5ca48347"
    },
    {
      "headline": "Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says",
      "source": "Yahoo",
      "datetime": 1759949139,
      "summary": "Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics (",
      "url": "https://finnhub.io/api/news?id=c302e5b61bd685ba464983de1216de8b164e4229bb67f1b2ccabe44038474cd8"
    },
    {
      "headline": "Why The Narrative Around J&J Is Shifting Amid Analyst Upgrades and Pharma Developments",
      "source": "Yahoo",
      "datetime": 1759943683,
      "summary": "Johnson & Johnson stock has recently seen its consensus analyst price target lifted from $179.64 to $185.13, marking an increase of approximately $5.49 as market sentiment improves. This upward revision comes as analysts anticipate renewed growth and express confidence in Johnson & Johnson's strateg",
      "url": "https://finnhub.io/api/news?id=bfe65b4ac0d8a8cadb5f78429819837869dad9321f8b069211fecca762a91b1e"
    },
    {
      "headline": "Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again",
      "source": "Yahoo",
      "datetime": 1759939802,
      "summary": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=cce9e17dcabb116791206efcff93ccd91af8a25d455e002aad7412c989be9650"
    },
    {
      "headline": "Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease",
      "source": "Yahoo",
      "datetime": 1759936980,
      "summary": "BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.",
      "url": "https://finnhub.io/api/news?id=f74d2ae582a28408223a0a5398e1b995b1a398278e9126f9f63d12a14aa49d64"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627206.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000192/xslF345X05/wk-form4_1757627206.xml"
    },
    {
      "form": "8-K",
      "date": "2025-09-09",
      "description": "jnj-20250908.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000190/jnj-20250908.htm"
    },
    {
      "form": "4",
      "date": "2025-09-05",
      "description": "xslF345X05/wk-form4_1757109644.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000186/xslF345X05/wk-form4_1757109644.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}